If you would like to learn more about future focusIR related events and roundtables, please submit your details here

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksABAL.L Regulatory News (ABAL)

  • There is currently no data for ABAL

Proposed Placing

11 Jun 2012 08:00

RNS Number : 0479F
Imaginatik PLC
11 June 2012
 

11 June 2012

Imaginatik Plc

 

("Imaginatik" or the "Company")

 

PROPOSED PLACING AND NOTICE OF GENERAL MEETING

 

Imaginatik plc (AIM: IMTK.L), the world's first full service innovation provider offering a range of technology products and consultancy, announces that it is proposing to raise up to £1million before expenses through a conditional placing of up to 333,333,333 new ordinary shares (the "Placing Shares") with institutional and other investors at a price of 0.3p per Placing Share (the "Placing"). The Company has received irrevocable commitments to subscribe for 285,833,333 Placing Shares and expressions of interest from certain Directors of the Company to subscribe for a further 47,500,000 Placing Shares in the Placing on the same terms. The Placing is being arranged by Northland Capital Partners Limited ("Northland") subject to the terms of a conditional agreement between the Company and Northland (the "Placing Agreement")

 

The Placing Shares will represent approximately 39 per cent. of the enlarged issued share capital of the Company.

 

Use of proceeds

 

Subject to the Placing Agreement becoming unconditional and not being terminated in accordance with its terms, the Placing will raise up to £1 million before the deduction of expenses payable by the Company. The net proceeds will be used to expand the Company's US based sales team, to add consultancy capacity in both the US and European markets, to further invest in the Company's technology and further develop its branding and marketing efforts.

 

Matt Cooper, Chairman of Imaginatik, commented:

 

"We are delighted with the support from new and existing investors. These funds will enable us to complete the transition from a software provider to the world's first full service innovation company and give us the platform from which to capitalise on this unique position in the market."

 

Related party transactions

 

The following shareholders, each of whom is a related party for the purposes of the AIM Rules by virtue of the extent of their interests in the existing ordinary shares, has agreed to subscribe for Placing Shares at the Placing Price as follows:

 

 

Percentage of existing ordinary shares held prior to the Placing

 

 

 

 

 

Placing participation

 

 

 

 

Number of Placing Shares to be acquired

 

 

Percentage of issued ordinary shares after Completion

Artemis Investment Management

 

15.37

£125,000

41,666,667

13.68

Octopus Asset Management

12.84

£50,000

16,666,667

9.37

 

The Board, other than Matt Cooper who as chairman of Octopus Asset Management is not independent for the purpose of the AIM Rules, considers, having consulted with the Company's Nominated Adviser, Northland Capital Partners Limited, that the participation in the Placing by Artemis Investment Management and Octopus Asset Management is in each case fair and reasonable so far as the shareholders of the Company are concerned.

 

Notice of General Meeting

 

The Placing is conditional, inter alia, on the approval of Imaginatik's shareholders and admission of the Placing Shares to trading on AIM. A circular containing a notice of the General Meeting is today being sent to Imaginatik's shareholders with details of the Placing and seeking the necessary approval of shareholders for the issue of the Placing Shares. The General Meeting will be held at the offices of Marriott Harrison, Staple Court, 11 Staple Inn Buildings, London WC1V 7QH at 11.00am on Wednesday 27 June 2012. A copy of the circular will be available on the Company's website; www.imaginatik.com.

 

The Placing Shares will be issued credited as fully paid and will rank pari passu in all respects with the existing ordinary shares, including the right to receive all dividends and other distributions declared on or after the date on which they are issued.

 

Application will be made for admission of the Placing Shares to trading on AIM ("Admission") and, subject to the requisite shareholder approval for the Placing being obtained at the General Meeting, it is expected that Admission will be effective on or around 8.00 am on 28 June 2012.

 

 

For further information please contact:

 

Imaginatik plc Tel: 020 7917 2975

Matt Cooper, Chairman / Shawn Taylor, CFO

Northland Capital Partners Limited Tel: 020 7796 8800

Gavin Burnell / Edward Hutton

John Howes / Alice Lane (Broking)

Newgate Threadneedle Tel: 020 7653 9850

Caroline Evans-Jones / Hilary Millar

 

About Imaginatik

Imaginatik provides a range of Innovation solutions comprised of consultancy, enterprise software and program management to deliver innovation results to companies such as The World Bank, NYSE, The Chubb Group of Insurance Companies, Boeing, Pfizer, Goodyear, Paccar, Kellogg and Cargill. Few companies possess the internal capability to consistently generate fresh ideas, identify those worth pursuing and reliably transform them into real, value-enhancing assets. Imaginatik's mission is to help these companies build sustainable innovation competencies.

 

Imaginatik is a public company whose shares are traded on the AIM market of the London Stock Exchange (LSE:IMTK.L) and is a World Economic Forum Technology Pioneer with offices in Boston, MA, and Winchester, UK. For more information visit www.imaginatik.com.

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
MSCFMMPTMBABBAT
Date   Source Headline
25th Jan 201211:30 amRNSHolding(s) in Company
23rd Jan 20127:01 amRNSContract Renewals worth £1.1m
3rd Jan 20127:00 amRNSDirectorate Change
22nd Dec 20117:00 amRNSContract extension
14th Dec 20117:00 amRNSLitigation Update
12th Dec 20117:00 amRNSContract Win
28th Nov 20117:00 amRNSHalf Yearly Report
28th Oct 20112:13 pmRNSChange of Adviser
28th Oct 201110:02 amRNSHolding(s) in Company
27th Oct 201110:45 amRNSHolding(s) in Company
13th Oct 20117:00 amRNSContract Extension
3rd Oct 201112:28 pmRNSDirectorate Change
26th Sep 20115:12 pmRNSResult of AGM
15th Sep 201110:24 amRNSHolding(s) in Company
2nd Sep 20113:25 pmRNSNotice of AGM
31st Aug 201111:46 amRNSHolding(s) in Company
26th Aug 20113:30 pmRNSResult of Open Offer and General Meeting
4th Aug 20119:32 amRNSPosting of Circular
2nd Aug 20117:15 amRNSProposed Placing, Subscription and Open Offer
2nd Aug 20117:00 amRNSFinal Results
29th Jul 201112:10 pmRNSNotice of Results
26th Apr 20117:00 amRNSIssue of Equity
14th Apr 20117:00 amRNSContract with the World Bank
1st Mar 20117:00 amRNSContract Wins and Trading Update
25th Jan 201111:22 amRNSWithdrawal of requisition of General Meeting
12th Jan 201111:01 amRNSHolding(s) in Company
11th Jan 20115:26 pmRNSIssue of Equity
22nd Dec 201012:24 pmRNSResult of General Meeting
22nd Dec 20107:00 amRNSFurther Requisition of General Meeting
16th Dec 20107:00 amRNSHalf Yearly Report
1st Dec 201010:08 amRNSNotice of General Meeting
19th Nov 20107:00 amRNSBoard Appointment
15th Nov 20103:28 pmRNSRequisition of General Meeting
11th Oct 20107:00 amRNSContract Extension with Pfizer
4th Oct 201011:58 amRNSShare Option Schemes
29th Sep 201011:41 amRNSResult of AGM
29th Sep 20107:00 amRNSAGM Statement
10th Sep 20105:00 pmRNSHolding in Company
10th Sep 20103:36 pmRNSHolding(s) in Company
10th Sep 20107:00 amRNSPilot Project Established with NASA
9th Sep 201012:47 pmRNSHolding(s) in Company
6th Sep 20104:14 pmRNSIssue of Equity
24th Aug 20103:16 pmRNSResult of General Meeting
18th Aug 20101:23 pmRNSMarket Update
6th Aug 20106:28 pmRNSPosting of Circular
30th Jul 20104:41 pmRNSHolding(s) in Company
27th Jul 20104:33 pmRNSPosting of Circular convening General Meeting
22nd Jul 201011:53 amRNSHolding(s) in Company
7th Jul 201011:04 amRNSSenior Management Team Appointments
23rd Jun 20107:00 amRNSFinal Results

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.